We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-11.31%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$957M
AUM Growth
-$152M
Cap. Flow
+$96.6M
Cap. Flow %
10.09%
Top 10 Hldgs %
58.48%
Holding
65
New
21
Increased
9
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$47.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$26.3M
3
PBYI icon
Puma Biotechnology
PBYI
+$24.6M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$17.1M
5
ANAB icon
AnaptysBio
ANAB
+$16.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$32.4M
2
KYNB
Kyntra Bio
KYNB
+$24.3M
3
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$13.4M
4
SAGE
Sage Therapeutics
SAGE
+$12.5M
5
KURA icon
Kura Oncology
KURA
+$8.36M

Sector Composition

Rank Sector Weight
1 Healthcare 98.79%
2 Miscellaneous 1.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$479M
$101M 10.54%
9,426,640
– –
XNCR icon
2
Xencor
XNCR
$1.94B
$74.7M 7.81%
2,501,557
– –
ARVN icon
3
Arvinas
ARVN
$600M
$61.6M 6.43%
1,528,031
+188,962
+14% +$8.84M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$61.5M 6.42%
3,346,301
-281,296
-8% -$5.47M
FATE icon
5
Fate Therapeutics
FATE
$291M
$52M 5.43%
2,341,875
+1,890,521
+419% +$47.8M
IRWD icon
6
Ironwood Pharmaceuticals
IRWD
$682M
$44.3M 4.63%
4,393,236
+21,828
+0.5% +$257K
ANAB icon
7
AnaptysBio
ANAB
$1.67B
$42.9M 4.48%
3,036,014
+1,069,914
+54% +$16.2M
NGNE icon
8
Neurogene
NGNE
$732M
$42M 4.39%
184,660
-11,134
-6% -$2.29M
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$41.4M 4.33%
2,823,141
+668,296
+31% +$11.2M
ASMB icon
10
Assembly Biosciences
ASMB
$694M
$38.4M 4.01%
215,890
+16,868
+8% +$3.62M
KURA icon
11
Kura Oncology
KURA
$1.13B
$34.9M 3.65%
3,511,690
-730,263
-17% -$8.36M
KYNB
12
Kyntra Bio
KYNB
$32.5M
$30.7M 3.2%
35,286
-24,403
-41% -$24.3M
IPHA
13
Innate Pharma
IPHA
$248M
$29.8M 3.12%
4,465,668
-79,786
-2% -$538K
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$27.5M 2.87%
357,849
+292,849
+451% +$26.3M
PRVL
15
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$27.4M 2.86%
2,248,306
– –
PBYI icon
16
Puma Biotechnology
PBYI
$468M
$21.4M 2.24%
+2,536,156
New +$24.6M
MRUS
17
DELISTED
Merus
MRUS
$20.8M 2.17%
1,715,962
-2,238
-0.1% -$35.4K
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$18.3M 1.91%
1,106,180
-375,231
-25% -$6.8M
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$2.52B
$16.5M 1.72%
371,208
+109,654
+42% +$5.69M
SGMO
20
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$14.7M 1.54%
+2,308,079
New +$17.1M
GMAB icon
21
Genmab
GMAB
$20.4B
$13.9M 1.45%
+653,981
New +$14.6M
ACAD icon
22
Acadia Pharmaceuticals
ACAD
$5.02B
$13.7M 1.43%
323,889
-176,111
-35% -$7.26M
DNLI icon
23
Denali Therapeutics
DNLI
$3.84B
$12.2M 1.28%
+698,101
New +$14.6M
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$11.5M 1.21%
+1,249,611
New +$11.9M
RNAC icon
25
Cartesian Therapeutics
RNAC
$290M
$11.1M 1.16%
153,257
– –
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2020 Portfolio in Review

As of Q1 2020, EcoR1 Capital held 65 positions worth $957M, down 14% from $1.11B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

EcoR1 Capital deployed $96.6M of net new capital in Q1 2020, opening 21 new positions and adding to 9 existing holdings. Its largest new stake was Puma Biotechnology: 2,536,156 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Kyntra Bio, an estimated $24.3M trimmed.

  • EcoR1 Capital's largest Q1 2020 buy was Puma Biotechnology: 2,536,156 shares worth $21.4M.
  • EcoR1 Capital added most to Fate Therapeutics in Q1 2020, an estimated $47.8M increase.
  • EcoR1 Capital's biggest Q1 2020 reduction was Kyntra Bio, cutting an estimated $24.3M.
  • EcoR1 Capital fully exited argenx in Q1 2020, selling an estimated $32.4M.
  • EcoR1 Capital's ten largest holdings make up 58% of its $957M portfolio in Q1 2020.
  • EcoR1 Capital opened 21 new positions and closed 14 in Q1 2020.
  • EcoR1 Capital's portfolio value fell 14% quarter-over-quarter to $957M.

Based on EcoR1 Capital's 13F filing for Q1 2020, filed 15 May 2020.